154 related articles for article (PubMed ID: 22905260)
1. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.
Weinstein S; Emmanuel R; Jacobi AM; Abraham A; Behlke MA; Sprague AG; Novobrantseva TI; Nagler A; Peer D
PLoS One; 2012; 7(8):e43343. PubMed ID: 22905260
[TBL] [Abstract][Full Text] [Related]
2. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
3. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1.
Sun X; Tang SC; Xu C; Wang C; Qin S; Du N; Liu J; Zhang Y; Li X; Luo G; Zhou J; Xu F; Ren H
J Cell Mol Med; 2015 Jun; 19(6):1357-65. PubMed ID: 25702703
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.
Tiemann K; Alluin JV; Honegger A; Chomchan P; Gaur S; Yun Y; Forman SJ; Rossi JJ; Chen RW
Leuk Lymphoma; 2011 Nov; 52(11):2148-54. PubMed ID: 21745168
[TBL] [Abstract][Full Text] [Related]
5. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.
Mohanty S; Mohanty A; Sandoval N; Tran T; Bedell V; Wu J; Scuto A; Murata-Collins J; Weisenburger DD; Ngo VN
Leuk Lymphoma; 2017 Mar; 58(3):676-688. PubMed ID: 27338091
[TBL] [Abstract][Full Text] [Related]
7. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
[TBL] [Abstract][Full Text] [Related]
9. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Klier M; Anastasov N; Hermann A; Meindl T; Angermeier D; Raffeld M; Fend F; Quintanilla-Martinez L
Leukemia; 2008 Nov; 22(11):2097-105. PubMed ID: 18685613
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
12. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
Mozos A; Royo C; Hartmann E; De Jong D; Baró C; Valera A; Fu K; Weisenburger DD; Delabie J; Chuang SS; Jaffe ES; Ruiz-Marcellan C; Dave S; Rimsza L; Braziel R; Gascoyne RD; Solé F; López-Guillermo A; Colomer D; Staudt LM; Rosenwald A; Ott G; Jares P; Campo E
Haematologica; 2009 Nov; 94(11):1555-62. PubMed ID: 19880778
[TBL] [Abstract][Full Text] [Related]
13. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
[TBL] [Abstract][Full Text] [Related]
14. Flipping the cyclin D1 switch in mantle cell lymphoma.
Hasanali Z; Sharma K; Epner E
Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
[TBL] [Abstract][Full Text] [Related]
15. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
[TBL] [Abstract][Full Text] [Related]
16. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
